# Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment

> **NCT01123980** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 521 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** biphasic insulin aspart 30
- **DRUG:** metformin
- **DRUG:** glimepiride
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT01123980
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 521 (ACTUAL)
- **Last updated:** 2017-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01123980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01123980, "Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT01123980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*